Finally! Be free from smoking

Archive for the ‘Non-Small-Cell’ Category

Debi wrote an intriguing post today on
Here’s a little taster
As there is no optimal treatment of non small cell lung cancer due to its resistance to common chemotherapeutics, we investigated the effect of human placenta-conditioned medium on tumor tissue. The human placenta constitutes a mixture of maternal and fetal origin and displays a variety of immunomodulatory aspects.

Read the rest of this post here

Debi wrote an intriguing post today on
Here’s a little taster
A drug, called tarceva, works better in patients who were screened for a particular gene mutation. Patients with this mutation live longer than those without the mutation.
The drugs, Tarceva and Iressa, seemingly show betterresults in people who have advanced non-small-cell lung cancer who also have certain mutations in the EGRF. They work by inhibiting the cancer cells’ ability to multiply.

Read the rest of this post here

Debi wrote an intriguing post today on
Here’s a little taster
Researchers found that whole-body PET/CT combined with cranial imaging helps pinpoint advanced nonsmall-cell lung cancer and prevent unnecessary thoracotomy in patients. However, the study also found that the strategy yielded false-positive outcomes that incorrectly upstaged the disease in some patients.

Read the rest of this post here

nospam@example.com (Clear the Smoke) wrote an intriguing post today on
Here’s a little taster
Activating mutations in the epidermal growth factor receptor gene (EGFR) confer hypersensitivity to the tyrosine kinase inhibitors gefitinib and erlotinib in patients with advanced non–small-cell lung cancer. We evaluated the feasibility of large-scale screening for EGFR mutations in such patients and analyzed the association between the mutations and the outcome of erlotinib treatment.

Read the rest of this post here

Debi wrote a good post today on
Here’s a little excerpt
A study examining erlotinib-bevacizumab combination therapy in patients with advanced non-small cell lung cancer (NSCLC) suggests that disease progression can be delayed with this therapy.
 
These findings were presented by Vincent Miller, MD at the 2009 Annual Meeting of the American Society of Clinical Oncology.

Read the rest of this great post here

Debi wrote an interesting post today on
Here’s a quick excerpt
A new strategy for treating non-small cell lung cancer increases the effectiveness of standard chemotherapy in patients with advanced stage disease, according to results presented at the American Society of Clinical Oncology meeting in Orlando.

Read the rest of this great post here

Debi wrote an interesting post today on
Here’s a quick excerpt
Data from the Phase III ZODIAC study in advanced non-small cell lung cancer patients, with the investigational drug vandetanib, were presented today at the American Society of Clinical Oncology (ASCO) meeting in Orlando. Results show that the study met its primary endpoint, demonstrating that the addition of vandetanib to docetaxel resulted in a statistically significant improvement in progression-free survival (PFS), the length of time a patient lives without their cancer growing.

Read the rest of this great post here

Debi wrote an interesting post today on
Here’s a quick excerpt
Hope. It’s an all-too-rare word for those who’re dealing with lung cancer, but recently came some hopeful news. If your parent or loved one has stage III or stage IV non-small-cell lung cancer (the most common kind), there’s a new clinical trial starting this month that you’ll want to ask his doctor about.

Read the rest of this great post here

Debi wrote an interesting post today on
Here’s a quick excerpt
 
NEW YORK (Reuters Health) – Concurrent chemoradiation is associated with the longest survival in patients with advanced non-small cell lung cancer (NSCLC), according to US and Chinese researchers.
However, senior investigator Dr. Feng-Ming Kong of the University of Michigan, Ann Arbor, told Reuters Health, “although high-doseradiation therapy and chemotherapy improve the treatment results, the long-term survival rates from this study remain poor.” She added that survival rates are “much better” in patients treated more recently.

Read the rest of this great post here

Debi wrote an interesting post today on
Here’s a quick excerpt
Tuesday, Cyclacel Pharmaceuticals Inc. said it began a Phase 2, open label, single arm, multicenter clinical trial of sapacitabine in patients with non-small cell lung cancer who have had one prior chemotherapy. The study builds on the observation of prolonged stable disease of four months or longer experienced by heavily pretreated non-small cell lung cancer patients involved in two Phase 1 studies of sapacitabine.

Read the rest of this great post here